Syndax Pharmaceuticals (NASDAQ: SNDX) reported a series of insider transactions involving its chief financial officer, Keith A. Goldan, in filings with the Securities and Exchange Commission.
Insider transactions and holdings
On February 6, 2026, Goldan sold 2,082 shares of Syndax common stock at $20.62 per share, producing proceeds of approximately $42,930. The Form 4 filing shows that the sale followed other activity in the immediate period surrounding early February.
Two days earlier, on February 4, 2026, Goldan acquired Syndax common stock through two separate transactions: one for 21,500 shares and a second for 30,750 shares. Both of those transactions are recorded at $0. Additionally, the filing shows a purchase of 1,219 shares at $8.48 on January 30, 2026.
Also on February 4, 2026, Goldan was awarded 118,000 stock options with an exercise price of $20.43 per share. Those options vest monthly over a four-year schedule and carry an expiration date of February 4, 2036.
Following the combined effect of the sales, purchases and the option grant, the disclosure states that Goldan directly owns 143,839 shares of Syndax common stock.
Company developments highlighted by analysts
The filing comes amid recent company updates and analyst commentary. Syndax showcased data for its FDA-approved menin inhibitor, Revuforj, at the 67th American Society of Hematology Annual Meeting. According to the company presentation noted in the filing, the data demonstrated a 77% overall response rate in relapsed or refractory patients with specified types of acute leukemia, and among responders 75% achieved measurable residual disease negativity.
Following Syndax’s presence at the ASH meeting, several brokerages reiterated positive ratings. B.Riley maintained a Buy rating and set a $33.00 price target, citing what it described as strong commercial momentum for Syndax’s partnered therapies. H.C. Wainwright also reiterated a Buy rating with a $40.00 price target, highlighting Revuforj’s reported real-world success in sustaining robust trial responses. TD Cowen reaffirmed a Buy rating after noting Syndax’s significant representation at the meeting, where both Revuforj and Niktimvo were featured in multiple presentations. The filing states these actions reflect continued interest and confidence in Syndax’s therapeutic portfolio.
Context and interpretation
The SEC Form 4 records a combination of purchases, a sale and an option award for the company’s CFO, and the company simultaneously disclosed encouraging clinical results and multiple analyst Buy reiterations. The filings and analyst notes together present a sequence of corporate and market developments that may be of interest to investors following Syndax.
Readers should note that the filings provide a factual record of transactions, option terms and analyst statements as disclosed on those dates.